NVO Wegovy launch momentum

PARAGRAPH 1 --- What happened: Novo Nordisk's newly launched weight-loss pill, Wegovy, has surged in U.S. demand, driving the Danish pharmaceutical giant's first-quarter results to smash expectations. Sales of Wegovy jumped 32% on a constant currency basis to reach DKK 96.8 billion, leading Novo Nordisk to hike its annual profit guidance. New data also shows high-dose Wegovy helped some patients lose nearly 28% of their weight, further boosting the drug's appeal.

PARAGRAPH 2 --- Market impact: The obesity drug market is expanding rapidly, with Novo Nordisk's innovative pricing model for Wegovy set to unlock a much larger market. Rival Eli Lilly's semaglutide (Wegovy's main competitor) has also seen strong demand, indicating a broader shift in patient preferences towards GLP-1 weight loss treatments. Novo Nordisk's stock appears attractively valued, with BMO Capital maintaining a Market Perform rating and a $45 price target.

PARAGRAPH 3 --- What to watch next: Investors should closely monitor Novo Nordisk's Q2 earnings release, scheduled for August 4, to gauge the sustainability of Wegovy's momentum. Additionally, regulatory approvals for Wegovy in new markets, such as Europe, will be crucial for further growth. Lastly, keep an eye on the technical level of Novo Nordisk's stock price, which could indicate a shift in investor sentiment towards the company's obesity drug franchise.